Trilogy Capital’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Trilogy Capital’s Portfolio PJP Stock Details PJP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.83M	Sell	15,476 -505	-3%	-$54.6K	0.07%	165
2026 Q1	$1.66M	Buy	15,981 +5	+0%	+$528	0.07%	162
2025 Q4	$1.67M	Sell	15,976 -115	-0.7%	-$11.6K	0.07%	158
2025 Q3	$1.49M	Sell	16,091 -564	-3%	-$49.4K	0.07%	162
2025 Q2	$1.33M	Buy	+16,655	New	+$1.33M	0.06%	160
2018 Q4	–	Sell	-443	Closed	-$33K	–	450
2018 Q3	$33K	Buy	443 +149	+51%	+$10.7K	﹤0.01%	228
2018 Q2	$20K	Hold	294	–	–	﹤0.01%	253
2018 Q1	$18K	Buy	+294	New	+$19.4K	﹤0.01%	230

Other funds holding PJP

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

SAM

Secure Asset Management Troy, Michigan $714M AUM 27.91% 1-Year Est. Return

Cordant Inc Portland, Oregon $278M AUM 23.17% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

HIA

Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

CBT

Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return

HWP

Highline Wealth Partners Sherman Oaks, California $493M AUM 19.33% 1-Year Est. Return

AAG

Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return

BTC

Bank & Trust Company Litchfield, Illinois $158M AUM 35.48% 1-Year Est. Return

Trilogy Capital's PJP Position: Q2 2026 in Review

Trilogy Capital reduced its Invesco Pharmaceuticals ETF (PJP) stake by 3.2% in Q2 2026, selling an estimated $54.6K and leaving 15,476 shares worth $1.83M. The position accounts for 0.07% of the portfolio, ranked #165.

Trilogy Capital first reported a position in PJP in Q1 2018 and has held it in 8 quarters since. 13 funds tracked by Wall St. Rank hold PJP as of Q2 2026.

Trilogy Capital held 15,476 shares of Invesco Pharmaceuticals ETF worth $1.83M as of Q2 2026.
Trilogy Capital sold 505 Invesco Pharmaceuticals ETF shares in Q2 2026, an estimated $54.6K.
Invesco Pharmaceuticals ETF made up 0.07% of Trilogy Capital's portfolio in Q2 2026, its #165 holding.
Trilogy Capital first reported a position in Invesco Pharmaceuticals ETF in Q1 2018 and has held it in 8 quarters since.
13 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q2 2026.

Based on Trilogy Capital's 13F filing for Q2 2026, filed 6 Jul 2026.